Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users

Hepatology

Volumn 56, Issue 2, 2012, Pages 544-554

  Munshaw, Supriya ^a   Hwang, Hyon S ^a   Torbenson, Michael ^a   Quinn, Jeffrey ^a   Hansen, Kasper D ^b   Astemborski, Jacquie ^a   Mehta, Shruti H ^b   Ray, Stuart C ^a   Thomas, David L ^a   Balagopal, Ashwin ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINESTERASE; TRANSCRIPTOME; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DEPENDENCE; DRUG METABOLISM; FEMALE; GENE EXPRESSION PROFILING; GENE LOSS; GENOTYPE; HEPATITIS C; HEPATITIS VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER PARENCHYMA; LONGITUDINAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA HYBRIDIZATION; RNA PURIFICATION; VALIDATION PROCESS; VIRUS LOAD;

ADULT; BUTYRYLCHOLINESTERASE; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; LASER CAPTURE MICRODISSECTION; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; METABOLISM, INBORN ERRORS; MIDDLE AGED; PORTAL SYSTEM; SUBSTANCE-RELATED DISORDERS;

EID: 84864353093     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25655     Document Type: Article

References (29)

1. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-348.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
3. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398, vi.
4. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250.
5. Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, et al. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 2010; 138: 2509-2518.
6. Lau DT, Luxon BA, Xiao SY, Beard MR, Lemon SM. Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. HEPATOLOGY 2005; 42: 273-281.
7. Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C, et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. HEPATOLOGY 2002; 35: 1247-1255.
8. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. HEPATOLOGY 2006; 43: 788-795.
9. Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48: 963-972.
10. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
11. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005; 33: e175.
12. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-315.
13. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3.
14. Liu WM, Mei R, Di X, Ryder TB, Hubbell E, Dee S, et al. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 2002; 18: 1593-1599.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Statist. Soc. Ser. B 1995; 57: 289-300.
16. Huang dW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, et al. DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007; 35(Web Server Iissue): W169-W175.
17. Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. HEPATOLOGY 2003; 38: 1458-1467.
18. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 1997; 48: 159-165.
19. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, Dean RA. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 1996; 279: 713-717.
20. Brzezinski MR, Abraham TL, Stone CL, Dean RA, Bosron WF. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem Pharmacol 1994; 48: 1747-1755.
21. Dean RA, Zhang J, Brzezinski MR, Bosron WF. Tissue distribution of cocaine methyl esterase and ethyl transferase activities: correlation with carboxylesterase protein. J Pharmacol Exp Ther 1995; 275: 965-971.
22. Salmon AY, Goren Z, Avissar Y, Soreq H. Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine. Clin Exp Pharmacol Physiol 1999; 26: 596-600.
23. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact 2008; 175: 83-87.
24. Ogunkeye OO, Roluga AI. Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests. Pathophysiology 2006; 13: 91-93.
25. Duysen EG, Li B, Carlson M, Li YF, Wieseler S, Hinrichs SH, et al. Increased hepatotoxicity and cardiac fibrosis in cocaine-treated butyrylcholinesterase knockout mice. Basic Clin Pharmacol Toxicol 2008; 103: 514-521.
26. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, Lockridge O. An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 1999; 55: 83-91.
27. Smith MW, Walters KA, Korth MJ, Fitzgibbon M, Proll S, Thompson JC, et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 2006; 130: 179-187.
28. Takahara Y, Takahashi M, Zhang QW, Wagatsuma H, Mori M, Tamori A, et al. Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients. World J Gastroenterol 2008; 14: 2010-2022.
29. Brosnan ME, Brosnan JT. Hepatic glutamate metabolism: a tale of 2 hepatocytes. Am J Clin Nutr 2009; 90: 857S-861S.